Search results
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...
Morningstar· 2 days agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Zacks via Yahoo Finance· 23 hours agoARC-9 is a phase Ib/II study evaluating the safety and efficacy of etrumadenant (E), a dual A2a/A2b...
Can macular degeneration affect people in their twenties?
Medical News Today· 2 days agoMacular degeneration in younger people is rare, but it can affect people in their twenties. Juvenile...
Citi maintains buy on Arcus Biosciences stock By Investing.com
Investing.com· 24 hours agoThe study showcased significant survival benefits for patients with third-line and beyond colorectal...
New treatment may extend survival for people with advanced colon cancer
UPI· 6 days agoPeople battling advanced colon cancers might have a new treatment option that could extend their...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 5 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
Lymphadenectomy Not Needed in Advanced Ovarian Cancer With Optimal Surgery
MedPage Today· 2 days agoOmitting lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or...
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal...
Benzinga· 1 day agoGilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response ...
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study...
KOIN News 6 Portland· 2 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 14 hours agoRemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88 PR Newswire YANTAI, China, June 3, 2024 YANTAI, China, June 3, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("
